Patients, pharmacy benefits managers and drugmakers alike are trying to figure out how to save money through further generics use and better prescription adherence.
The good news from IMS Institute for Healthcare Informatics: Using prescription medicines properly could save $200 billion in annual U.S. healthcare costs. More good news, at least for the pharma business: The institute's ideas for saving money don't all translate to less spending on drugs, branded or otherwise.
Generic drugs already have cost on their side when competing with pricey brands. But according to a new study in Health Affairs, older meds may actually be more effective, too.
It's no big secret that international drugmakers are miffed at India. Revoking a few drug patents and overriding others will do that. But India's own pharma companies have their own beef with government policy--namely government pricing policies.
South Africa plans to revamp its intellectual-property laws to make it more difficult for pharma companies to win protection for new versions of older drugs. The move comes soon after India's top court backed strict requirements for drug patents.
How is a generic drug's label different from the drug itself? That was one of the many questions posed yesterday as the generics-liability case had its Supreme Court airing.
It's confirmed: Another study shows that U.S. drug spending dropped ever so slightly last year. The obvious culprit is generic drugs, with major blockbusters such as Pfizer's ($PFE) Lipitor and AstraZeneca's ($AZN) Seroquel IR now facing cheap rivals.
The Supreme Court is hopping with pharma news these days. As the top U.S. court prepares to hear arguments tomorrow in the big generics-liability case, some key lawmakers in the generics world are balking at the whole federal-preemption idea.
Generic drugmakers are feeling a little taken advantage of. They produce 80% of the drugs used in the U.S. Their products are saving federal health programs billions of dollars and they are now helping cover some of the FDA budget through user fees.
India's Cipla and its namesake in South Africa, Cipla Medpro, may share a moniker but they haven't seen eye-to-eye on what it will take to share ownership.